The firm said that its CE-marked ePlex Blood Culture Identification fungal pathogen panel is the first of three tests that will become part of its sepsis solution.
The RNA-based blood test takes less than five hours to detect the presence or absence of infection in patients who may have sepsis.
The infectious disease diagnostics firm will initially receive $40 million from CRG, most of which will go towards paying down existing debt.
The platform uses a fluidics-based method to lyse blood cells and concentrate pathogens from patient samples.
The firm is developing a sepsis and SIRS diagnostic that combines its own molecule counting technology with Thermo Fisher's procalcitonin assay.
The firm's GI panel has also been recently evaluated in pediatric populations, demonstrating a marked increase in overall pathogen detection.
A hospital study demonstrated an average total cost saving of around $25,000 for each patient with candidemia.
T2 and Allergan will develop a novel diagnostic panel for the detection of Gram-negative bacterial species and antibiotic resistance in patients with bacterial infections.
The research aims to validate new predictive tests that would enable development of diagnostic and therapeutic solutions to fight sepsis.
Researchers have shown that metagenomic sequencing on the MinIon can identify the pathogen and antimicrobial resistance profile of UTIs in several hours.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.